GlaxoSmithKline PLC

LSE:GSK UK Drug Manufacturers - General
Market Cap
$955.93 Million
GBX7.86 Trillion GBX
Market Cap Rank
#29086 Global
#455 in UK
Share Price
GBX1956.00
Change (1 day)
-0.84%
52-Week Range
GBX1264.00 - GBX2268.00
All Time High
GBX2268.00
Categories
Companies in UK Drug Manufacturers - General
About

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more

GlaxoSmithKline PLC (GSK) - Net Assets

Latest net assets as of September 2025: GBX15.75 Billion GBX

Based on the latest financial reports, GlaxoSmithKline PLC (GSK) has net assets worth GBX15.75 Billion GBX as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX61.34 Billion) and total liabilities (GBX45.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX15.75 Billion
% of Total Assets 25.68%
Annual Growth Rate 6.64%
5-Year Change -37.11%
10-Year Change 47.4%
Growth Volatility 103.92

GlaxoSmithKline PLC - Net Assets Trend (1986–2024)

This chart illustrates how GlaxoSmithKline PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for GlaxoSmithKline PLC (1986–2024)

The table below shows the annual net assets of GlaxoSmithKline PLC from 1986 to 2024.

Year Net Assets Change
2024-12-31 GBX13.09 Billion +2.27%
2023-12-31 GBX12.79 Billion +26.73%
2022-12-31 GBX10.10 Billion -52.69%
2021-12-31 GBX21.34 Billion +2.57%
2020-12-31 GBX20.81 Billion +13.35%
2019-12-31 GBX18.36 Billion +399.92%
2018-12-31 GBX3.67 Billion +5.25%
2017-12-31 GBX3.49 Billion -29.70%
2016-12-31 GBX4.96 Billion -44.10%
2015-12-31 GBX8.88 Billion +79.86%
2014-12-31 GBX4.94 Billion -36.82%
2013-12-31 GBX7.81 Billion +15.78%
2012-12-31 GBX6.75 Billion -23.56%
2011-12-31 GBX8.83 Billion -9.42%
2010-12-31 GBX9.74 Billion -9.28%
2009-12-31 GBX10.74 Billion +29.14%
2008-12-31 GBX8.32 Billion -16.06%
2007-12-31 GBX9.91 Billion +2.72%
2006-12-31 GBX9.65 Billion +27.45%
2005-12-31 GBX7.57 Billion +27.51%
2004-12-31 GBX5.94 Billion +2.29%
2003-12-31 GBX5.80 Billion -21.44%
2002-12-31 GBX7.39 Billion -12.02%
2001-12-31 GBX8.40 Billion -6.23%
2000-12-31 GBX8.96 Billion +180.46%
1999-12-31 GBX3.19 Billion +15.35%
1998-12-31 GBX2.77 Billion +46.46%
1997-12-31 GBX1.89 Billion +49.17%
1996-12-31 GBX1.27 Billion +473.30%
1995-12-31 GBX221.00 Million -61.54%
1995-06-30 GBX574.69 Million -88.84%
1994-06-30 GBX5.15 Billion +10.56%
1993-06-30 GBX4.66 Billion +27.97%
1992-06-30 GBX3.64 Billion +10.88%
1991-06-30 GBX3.28 Billion +17.01%
1990-06-30 GBX2.81 Billion +21.27%
1989-06-30 GBX2.31 Billion +28.29%
1988-06-30 GBX1.80 Billion +23.16%
1987-06-30 GBX1.46 Billion +33.09%
1986-06-30 GBX1.10 Billion --

Equity Component Analysis

This analysis shows how different components contribute to GlaxoSmithKline PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 779600000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings GBX7.80 Billion 57.03%
Common Stock GBX1.35 Billion 9.86%
Other Comprehensive Income GBX1.45 Billion 10.61%
Other Components GBX3.08 Billion 22.50%
Total Equity GBX13.67 Billion 100.00%

GlaxoSmithKline PLC Competitors by Market Cap

The table below lists competitors of GlaxoSmithKline PLC ranked by their market capitalization.

Company Market Cap
Kijcharoen Engineering Electric PCL
BK:KJL
 		$8.74 Million
Eastern Power Group Public Company Limited
BK:EP
 		$8.74 Million
Ikena Oncology Inc
NASDAQ:IKNA
 		$8.74 Million
Chicago Rivet & Machine Co
NYSE MKT:CVR
 		$8.74 Million
Darya-Varia Laboratoria Tbk
JK:DVLA
 		$8.73 Million
Peloton Minerals Corporation
OTCQB:PMCCF
 		$8.73 Million
Propert & Buil
TA:PTBL
 		$8.73 Million
CATENON SA INH. EO-02
F:8Y9
 		$8.73 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GlaxoSmithKline PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 13,347,000,000 to 13,671,000,000, a change of 324,000,000 (2.4%).
  • Net income of 2,575,000,000 contributed positively to equity growth.
  • Dividend payments of 2,444,000,000 reduced retained earnings.
  • New share issuances of 20,000,000 increased equity.
  • Other comprehensive income decreased equity by 146,000,000.
  • Other factors increased equity by 319,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX2.58 Billion +18.84%
Dividends Paid GBX2.44 Billion -17.88%
Share Issuances GBX20.00 Million +0.15%
Other Comprehensive Income GBX-146.00 Million -1.07%
Other Changes GBX319.00 Million +2.33%
Total Change GBX- 2.43%

Book Value vs Market Value Analysis

This analysis compares GlaxoSmithKline PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 592.62x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 4249.37x to 592.62x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1986-06-30 GBX0.46 GBX1956.00 x
1987-06-30 GBX0.61 GBX1956.00 x
1988-06-30 GBX0.75 GBX1956.00 x
1989-06-30 GBX0.96 GBX1956.00 x
1990-06-30 GBX0.57 GBX1956.00 x
1991-06-30 GBX0.67 GBX1956.00 x
1992-06-30 GBX0.74 GBX1956.00 x
1993-06-30 GBX0.94 GBX1956.00 x
1994-06-30 GBX1.03 GBX1956.00 x
1995-06-30 GBX0.08 GBX1956.00 x
1995-12-31 GBX0.02 GBX1956.00 x
1996-12-31 GBX0.22 GBX1956.00 x
1997-12-31 GBX0.32 GBX1956.00 x
1998-12-31 GBX0.46 GBX1956.00 x
1999-12-31 GBX0.54 GBX1956.00 x
2000-12-31 GBX1.57 GBX1956.00 x
2001-12-31 GBX1.54 GBX1956.00 x
2002-12-31 GBX1.39 GBX1956.00 x
2003-12-31 GBX1.09 GBX1956.00 x
2004-12-31 GBX1.24 GBX1956.00 x
2005-12-31 GBX1.60 GBX1956.00 x
2006-12-31 GBX2.06 GBX1956.00 x
2007-12-31 GBX2.16 GBX1956.00 x
2008-12-31 GBX1.90 GBX1956.00 x
2009-12-31 GBX2.45 GBX1956.00 x
2010-12-31 GBX2.17 GBX1956.00 x
2011-12-31 GBX1.97 GBX1956.00 x
2012-12-31 GBX1.46 GBX1956.00 x
2013-12-31 GBX1.78 GBX1956.00 x
2014-12-31 GBX1.10 GBX1956.00 x
2015-12-31 GBX1.31 GBX1956.00 x
2016-12-31 GBX0.29 GBX1956.00 x
2017-12-31 GBX-0.02 GBX1956.00 x
2018-12-31 GBX1.10 GBX1956.00 x
2019-12-31 GBX2.99 GBX1956.00 x
2020-12-31 GBX3.62 GBX1956.00 x
2021-12-31 GBX4.64 GBX1956.00 x
2022-12-31 GBX2.60 GBX1956.00 x
2023-12-31 GBX3.25 GBX1956.00 x
2024-12-31 GBX3.30 GBX1956.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently GlaxoSmithKline PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 18.84%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.21%
  • • Asset Turnover: 0.53x
  • • Equity Multiplier: 4.35x
  • Recent ROE (18.84%) is below the historical average (101.38%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1986 36.70% 27.99% 0.79x 1.65x GBX291.00 Million
1987 35.17% 29.29% 0.74x 1.63x GBX365.00 Million
1988 32.57% 28.22% 0.72x 1.61x GBX402.60 Million
1989 30.03% 26.77% 0.74x 1.51x GBX458.90 Million
1990 29.54% 25.39% 0.71x 1.64x GBX533.80 Million
1991 27.46% 25.93% 0.59x 1.79x GBX560.20 Million
1992 28.92% 25.22% 0.72x 1.59x GBX675.80 Million
1993 26.55% 24.48% 0.66x 1.64x GBX752.40 Million
1994 25.85% 22.97% 0.72x 1.57x GBX796.40 Million
1995 253.19% 16.04% 0.80x 19.74x GBX998.26 Million
1995 1602.20% 13.90% 1.23x 93.86x GBX1.45 Billion
1996 163.02% 23.94% 1.00x 6.79x GBX1.87 Billion
1997 100.38% 23.18% 0.95x 4.58x GBX1.67 Billion
1998 67.95% 23.00% 0.85x 3.46x GBX1.57 Billion
1999 57.64% 21.33% 0.81x 3.32x GBX1.50 Billion
2000 53.97% 23.02% 0.84x 2.80x GBX3.39 Billion
2001 41.15% 15.10% 0.93x 2.92x GBX2.35 Billion
2002 59.79% 18.55% 0.95x 3.39x GBX3.28 Billion
2003 88.75% 20.94% 1.01x 4.19x GBX3.98 Billion
2004 68.27% 19.55% 0.87x 4.01x GBX3.34 Billion
2005 64.14% 21.65% 0.80x 3.72x GBX3.96 Billion
2006 57.42% 23.20% 0.91x 2.72x GBX4.45 Billion
2007 54.30% 22.95% 0.73x 3.23x GBX4.25 Billion
2008 58.03% 18.90% 0.62x 4.97x GBX3.81 Billion
2009 55.28% 19.50% 0.66x 4.28x GBX4.53 Billion
2010 18.39% 5.76% 0.68x 4.73x GBX745.30 Million
2011 65.50% 19.21% 0.67x 5.11x GBX4.46 Billion
2012 77.44% 17.02% 0.64x 7.14x GBX3.92 Billion
2013 77.69% 20.51% 0.63x 6.01x GBX4.74 Billion
2014 64.65% 11.98% 0.57x 9.54x GBX2.33 Billion
2015 164.69% 35.20% 0.45x 10.45x GBX7.91 Billion
2016 81.14% 3.27% 0.47x 52.56x GBX799.60 Million
2017 0.00% 5.08% 0.54x 0.00x GBX1.54 Billion
2018 83.10% 11.75% 0.53x 13.32x GBX3.19 Billion
2019 38.76% 13.76% 0.42x 6.65x GBX3.45 Billion
2020 39.41% 16.86% 0.42x 5.51x GBX4.29 Billion
2021 29.13% 17.76% 0.31x 5.25x GBX2.88 Billion
2022 141.12% 51.00% 0.49x 5.68x GBX13.90 Billion
2023 36.92% 16.25% 0.51x 4.42x GBX3.59 Billion
2024 18.84% 8.21% 0.53x 4.35x GBX1.21 Billion

Industry Comparison

This section compares GlaxoSmithKline PLC's net assets metrics with peer companies in the Drug Manufacturers - General industry.

No peer company data available for comparison.